GSK Statement in Response to Vote on Availability of Avandia

barbara.lempert GSK Statement in Response to FDA Advisory Committee’s Vote on Availability of Avandia (Rosiglitazone) PHILADELPHIA, June 6, 2013 – GlaxoSmithKline [NYSE: GSK] ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS